(Press-News.org) Contact information: Vicki Cohn
vcohn@liebertpub.com
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News
New study shows a breadth of antisense drug activity across many different organs
New Rochelle, NY, December 10, 2013—Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Nucleic Acid Therapeutics website.
Gene Hung, Xiaokun Xiao, Raechel Peralta, Gourab Bhattacharjee, Sue Murray, Dan Norris, Shuling Guo, and Brett Monia, Isis Pharmaceuticals, Carlsbad, CA, developers of antisense therapeutics, compared two antisense drug chemistries (Generation 2.0 and 2.5) designed to target a gene that is expressed by virtually all cells in mice and non-human primates. They demonstrated antisense activity in many tissues and cell types, including liver, kidney, lung, muscle, adipose, adrenal gland, and peripheral nerves. The Generation 2.5 antisense compound was more effective in a wider range of tissues, according to the results presented in the article "Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals."
"This seminal work addresses one of the most important questions facing the field, the demonstration and evaluation of multiple organ targeting by Nucleic Acid Therapeutics," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. "This publication provides a benchmark for convergent analyses in multiple models for preclinical efficacy evaluation."
Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.
INFORMATION:
About the Journal
Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website.
About the Society
The Oligonucleotide Therapeutics Society is an open, nonprofit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Human Gene Therapy, Human Gene Therapy Methods, Human Gene Therapy Clinical Development, ASSAY and Drug Development Technologies, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
http://www.liebertpub.com
New study shows a breadth of antisense drug activity across many different organs
2013-12-11
ELSE PRESS RELEASES FROM THIS DATE:
Exercise alleviates sexual side-effects of antidepressants in women, study shows
2013-12-11
Exercise alleviates sexual side-effects of antidepressants in women, study shows
Findings could lead to new treatment for sexual dysfuntion in women taking antidepressants
AUSTIN, Texas – New psychology research, which could have important public health implications ...
Malnourished children still have hope beyond first 1,000 days
2013-12-11
Malnourished children still have hope beyond first 1,000 days
BYU research shows early developmental damage can be reversed
Children who are malnourished during their first 1000 days (conception to age 2) often experience developmental setbacks that affect them for ...
Early initiation of ER palliative care consultations resulted in shorter hospital stays
2013-12-11
Early initiation of ER palliative care consultations resulted in shorter hospital stays
The results indicate that Accountable Care Organizations could be spending health care dollars more wisely, thus sharing in the savings it achieves for the Medicare program
New ...
NREL reports soft costs now largest piece of solar installation total cost
2013-12-11
NREL reports soft costs now largest piece of solar installation total cost
Two detailed reports from the Energy Department's National Renewable Energy Laboratory (NREL) find that solar financing and other non-hardware costs — often referred ...
Food and Chemical Toxicology Editor-in-Chief, A. Wallace Hayes, publishes response to letters to the editor
2013-12-11
Food and Chemical Toxicology Editor-in-Chief, A. Wallace Hayes, publishes response to letters to the editor
Cambridge, MA, December 10, 2013 – The following statement will be published in the journal, Food and Chemical Toxicology, alongside a selection of letters to the ...
NASA: Fire vs. ice: The science of ISON at perihelion
2013-12-11
NASA: Fire vs. ice: The science of ISON at perihelion
After a year of observations, scientists waited with bated breath on Nov. 28, 2013, as Comet ISON made its closest approach to the sun, known as perihelion. Would the comet disintegrate in ...
Researchers to present event-free and overall survival results from NeoALTTO trial
2013-12-11
Researchers to present event-free and overall survival results from NeoALTTO trial
SAN ANTONIO — Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or ...
High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
2013-12-11
High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
SAN ANTONIO — Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from ...
Study identifies highly effective treatment option for patients with HER2-positive breast cancer
2013-12-11
Study identifies highly effective treatment option for patients with HER2-positive breast cancer
SAN ANTONIO — Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal ...
Combined therapy linked to lower chance of recurrence in women with small, HER2+ breast cancers
2013-12-11
Combined therapy linked to lower chance of recurrence in women with small, HER2+ breast cancers
SAN ANTONIO— In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted ...